Dr. Xiaozhong Chen 陈晓钟
Chief Physician
Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Radiation therapy for head and neck tumors, with a primary focus on the treatment of nasopharyngeal carcinoma.
Dr. Chen is Chief Physician and Director of Head and Neck Radiation Therapy at Zhejiang Cancer Hospital. The doctor has published over 40 papers on nasopharyngeal carcinoma, led seven research projects, and edited or contributed to six books. Dr. Chen participated in developing national guidelines for nasopharyngeal carcinoma staging and intensity-modulated radiation therapy.
Professional roles
- Vice Chair, Nasopharyngeal Carcinoma Professional Committee, China Anti-Cancer Association
- Chair, Nasopharyngeal Carcinoma Professional Committee, Zhejiang Anti-Cancer Association
- Member, Chinese Nasopharyngeal Carcinoma Clinical Staging Working Committee
- Editorial Board Member, Cancer; International Journal of Oncology; Chinese Journal of Oncology; World Journal of Oncology
Name order: in Chinese the family name comes first (Chen Xiaozhong). Papers usually list the name as Xiaozhong Chen or Chen X.
Selected publications
99 papers on PubMed matched by name and affiliation; 34 as first or senior author since 2016. Most recent first- or senior-author papers:
- EClinicalMedicine, 2026 (senior author): Efficacy and safety of neoadjuvant chemotherapy with toripalimab in locally advanced nasopharyngeal carcinoma: a phase II trial and biological correlate analysis. PubMed 43022375
- Int J Cancer, 2026 (senior author): Penpulimab and Gemcitabine With or Without Anlotinib in Metastatic Nasopharyngeal Carcinoma: A Randomized, Open-Label, Multicenter Phase 2 Study. PubMed 42093316
- BMC Med, 2026 (senior author): Randomized, multicenter phase 3 study evaluating radiotherapy versus concurrent chemoradiotherapy in nasopharyngeal carcinoma patients achieving CR/PR after induction chemotherapy. PubMed 42436536
- Br J Hosp Med (Lond), 2025 (senior author): Recombinant Human Thrombopoietin Combined With Avatrombopag for Chemoradiotherapy-Induced Thrombocytopenia in Nasopharyngeal Carcinoma: A Prospective, Randomized Controlled Trial. PubMed 40994374
- J Geriatr Oncol, 2025 (senior author): Concurrent chemotherapy for older patients with locoregionally advanced nasopharyngeal carcinoma: A randomized clinical trial. PubMed 40378722
- Neoplasia, 2025 (senior author): Granulocyte-macrophage colony-stimulating factor for newly diagnosed glioblastoma. PubMed 40090128
- Head Neck, 2025 (senior author): Evaluating the reduction of elective radiotherapy fields for de novo metastatic nasopharyngeal carcinoma in the immunotherapy era. PubMed 39318329
- Head Neck, 2025 (senior author): Mecapegfilgrastim for the prophylaxis of chemotherapy-induced neutropenia in locally advanced nasopharyngeal carcinoma: A prospective phase II clinical study. PubMed 39129235
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion